BioCentury | Jul 25, 2020
Management Tracks

New CFOs for Generation Bio, IQVia; plus changes at Gracell, AskBio, Replimune, Triplet, Twist, Cellectis, Verrica and more

...Steve Parkinson, who remains president and CEO. Corr is co-founder and managing general partner of Auven Therapeutics...
BioCentury | Apr 27, 2020
Finance

ADC renews IPO bid as first regulatory filing looms

...among publicly traded biotechs. The company has raised $558.6 million in equity since its inception. Auven Therapeutics...
BioCentury | Jun 13, 2019
Financial News

June 13 Financial Quick Takes: Hansoh prices $1B HKEX IPO; plus Provention, Genome Medical, InGeneron and more

...$276 million. Undisclosed new and existing investors participated; investors in the round's 2017 close include Auven Therapeutics...
BioCentury | May 18, 2018
Finance

China comes to Europe

...Investors Technology Disease area ADC Therapeutics S.A. (Switzerland) $200.0 Undisclosed Redmile Group , AstraZeneca plc, Auven Therapeutics...
BioCentury | Nov 30, 2017
Preclinical News

Resolvins keep tumor debris from stimulating tumor growth

...as resolvin analogues of the D and E series for clinical cancer trials." In 2010, Auven Therapeutics Management LLLP...
...RX-10045, from Resolvyx Pharmaceuticals Inc. for all ophthalmic indications (see BioCentury, Nov. 1, 2010) . Michael Leviten Auven Therapeutics Management LLLP Beth...
BioCentury | Oct 27, 2017
Financial News

ADC raises $200M private placement

...conjugate company ADC Therapeutics S.A. (Épalinges, Switzerland) raised $200 million in a private placement from Auven Therapeutics...
...ADC Therapeutics S.A. , Épalinges, Switzerland Jaime De Leon ADCT-301 ADCT-402 ADCT-502 MEDI3726 AstraZeneca plc CD19 CD25 HER2 Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) ADC Therapeutics S.A. Auven Therapeutics...
BioCentury | Oct 26, 2017
Finance

Pays to stay private

...to raise capital.” “We keep the company IPO ready.” Chris Martin, ADC Therapeutics Existing investors Auven Therapeutics...
BioCentury | Oct 23, 2017
Financial News

ADC Therapeutics raises $200M

...conjugate company ADC Therapeutics S.A. (Épalinges, Switzerland) raised $200 million in a private placement from Auven Therapeutics...
...unit to co-develop two programs, including MEDI3726 (see BioCentury Extra, Oct. 15, 2013) . Jaime De Leon ADCT-301 ADCT-402 ADCT-502 HuMax-TAC-ADC MEDI3726 Auven Therapeutics Management LLLP AstraZeneca...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

...Xigen S.A. Brimapitide Idiopathic sudden sensorineural hearing loss (ISSNHL) Top-line Ph III HEALOS data Fall Auven Therapeutics Management LLLP...
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...Clough Capital Partners , Wellington Management , other investors ADC Therapeutics S.a.r.l. (Switzerland) Undisclosed $105.0 Auven Therapeutics...
Items per page:
1 - 10 of 60
BioCentury | Jul 25, 2020
Management Tracks

New CFOs for Generation Bio, IQVia; plus changes at Gracell, AskBio, Replimune, Triplet, Twist, Cellectis, Verrica and more

...Steve Parkinson, who remains president and CEO. Corr is co-founder and managing general partner of Auven Therapeutics...
BioCentury | Apr 27, 2020
Finance

ADC renews IPO bid as first regulatory filing looms

...among publicly traded biotechs. The company has raised $558.6 million in equity since its inception. Auven Therapeutics...
BioCentury | Jun 13, 2019
Financial News

June 13 Financial Quick Takes: Hansoh prices $1B HKEX IPO; plus Provention, Genome Medical, InGeneron and more

...$276 million. Undisclosed new and existing investors participated; investors in the round's 2017 close include Auven Therapeutics...
BioCentury | May 18, 2018
Finance

China comes to Europe

...Investors Technology Disease area ADC Therapeutics S.A. (Switzerland) $200.0 Undisclosed Redmile Group , AstraZeneca plc, Auven Therapeutics...
BioCentury | Nov 30, 2017
Preclinical News

Resolvins keep tumor debris from stimulating tumor growth

...as resolvin analogues of the D and E series for clinical cancer trials." In 2010, Auven Therapeutics Management LLLP...
...RX-10045, from Resolvyx Pharmaceuticals Inc. for all ophthalmic indications (see BioCentury, Nov. 1, 2010) . Michael Leviten Auven Therapeutics Management LLLP Beth...
BioCentury | Oct 27, 2017
Financial News

ADC raises $200M private placement

...conjugate company ADC Therapeutics S.A. (Épalinges, Switzerland) raised $200 million in a private placement from Auven Therapeutics...
...ADC Therapeutics S.A. , Épalinges, Switzerland Jaime De Leon ADCT-301 ADCT-402 ADCT-502 MEDI3726 AstraZeneca plc CD19 CD25 HER2 Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) ADC Therapeutics S.A. Auven Therapeutics...
BioCentury | Oct 26, 2017
Finance

Pays to stay private

...to raise capital.” “We keep the company IPO ready.” Chris Martin, ADC Therapeutics Existing investors Auven Therapeutics...
BioCentury | Oct 23, 2017
Financial News

ADC Therapeutics raises $200M

...conjugate company ADC Therapeutics S.A. (Épalinges, Switzerland) raised $200 million in a private placement from Auven Therapeutics...
...unit to co-develop two programs, including MEDI3726 (see BioCentury Extra, Oct. 15, 2013) . Jaime De Leon ADCT-301 ADCT-402 ADCT-502 HuMax-TAC-ADC MEDI3726 Auven Therapeutics Management LLLP AstraZeneca...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

...Xigen S.A. Brimapitide Idiopathic sudden sensorineural hearing loss (ISSNHL) Top-line Ph III HEALOS data Fall Auven Therapeutics Management LLLP...
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...Clough Capital Partners , Wellington Management , other investors ADC Therapeutics S.a.r.l. (Switzerland) Undisclosed $105.0 Auven Therapeutics...
Items per page:
1 - 10 of 60